The NKIRAS2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population derived from the human Raji B lymphocyte line. This model introduces a loss-of-function modification in the NKIRAS2 gene, which encodes the kappaB-Ras2 protein, an atypical small GTPase. The polyclonal format provides a heterogeneous knockout pool, avoiding clonal selection artifacts and enabling robust representation of genetic variability. These cells serve as a versatile tool for studying negative regulatory mechanisms of NF-??B signaling in a lymphoma-relevant cellular background.
The Raji parental cell line originates from a Burkitt lymphoma patient and is Epstein-Barr virus (EBV) positive, maintaining key B-cell characteristics including antibody production and antigen presentation. EBV-driven latency programs confer continuous proliferation and constitutive activation of NF-??B and other signaling pathways, making Raji cells a well-established model for investigating lymphomagenesis, immune signaling dynamics, and therapeutic responses in B-cell malignancies.
NKIRAS2 encodes kappaB-Ras2, which negatively regulates NF-??B signaling by binding to and stabilizing I??B proteins, primarily NFKBIA (I??B??) and NFKBIB (I??B??). This stabilization prevents their phosphorylation by the IKK complex??comprising CHUK (IKK??) and IKBKB (IKK??)??and subsequent degradation, thereby blocking nuclear translocation of NF-??B transcription factors RELA (p65) and NFKB1 (p50). As a result, transcription of pro-inflammatory and anti-apoptotic target genes such as BCL2, IL6, and TNF is attenuated. Upstream stimuli including TNF-alpha, IL-1, lipopolysaccharide, and CD40 ligand activate the canonical IKK/NF-??B cascade, counterbalanced by NKIRAS2-mediated restraint. In the knockout background, loss of kappaB-Ras2 is expected to enhance I??B degradation and elevate NF-??B activity.
Within the Raji cellular context, NKIRAS2 disruption permits dissection of NF-??B dynamics in an environment already exhibiting basal pathway activation due to EBV oncoproteins. This model is particularly relevant for studying B-cell lymphomas, autoimmune disorders, and inflammatory diseases where aberrant NF-??B signaling contributes to pathogenesis. It facilitates investigation of tumor suppressor functions attributed to NKIRAS2 and the identification of potential therapeutic targets that exploit negative feedback loops controlling NF-??B.
Researchers can employ these polyclonal knockout cells in a range of functional assays. Western blotting can assess I??B?? protein stability, while NF-??B luciferase reporter assays quantitatively measure pathway activity. Co-immunoprecipitation experiments can evaluate interactions between kappaB-Ras2 and NFKBIB, and RT-qPCR can profile transcriptional changes in downstream targets such as IL6 and BCL2. Flow cytometry-based apoptosis assays provide insights into the knockout’s impact on cell survival and drug sensitivity. Overall, this model offers a robust platform for probing negative regulation of NF-??B signaling and for preclinical therapeutic evaluation. For more information, please contact Ascent Research.
